Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.52
MRK's Cash to Debt is ranked higher than
59% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. MRK: 0.52 )
MRK' s 10-Year Cash to Debt Range
Min: 0.32   Max: 2.45
Current: 0.52

0.32
2.45
Equity to Asset 0.44
MRK's Equity to Asset is ranked higher than
57% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. MRK: 0.44 )
MRK' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.53
Current: 0.44

0.34
0.53
Interest Coverage 7.94
MRK's Interest Coverage is ranked higher than
56% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.14 vs. MRK: 7.94 )
MRK' s 10-Year Interest Coverage Range
Min: 3.31   Max: 44.62
Current: 7.94

3.31
44.62
F-Score: 6
Z-Score: 3.12
M-Score: -2.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.64
MRK's Operating margin (%) is ranked higher than
82% of the 861 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.67 vs. MRK: 13.64 )
MRK' s 10-Year Operating margin (%) Range
Min: 5.15   Max: 43.77
Current: 13.64

5.15
43.77
Net-margin (%) 12.50
MRK's Net-margin (%) is ranked higher than
84% of the 861 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. MRK: 12.50 )
MRK' s 10-Year Net-margin (%) Range
Min: 1.87   Max: 47.04
Current: 12.5

1.87
47.04
ROE (%) 11.18
MRK's ROE (%) is ranked higher than
83% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. MRK: 11.18 )
MRK' s 10-Year ROE (%) Range
Min: 1.52   Max: 48.6
Current: 11.18

1.52
48.6
ROA (%) 5.18
MRK's ROA (%) is ranked higher than
79% of the 914 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. MRK: 5.18 )
MRK' s 10-Year ROA (%) Range
Min: 0.79   Max: 18.45
Current: 5.18

0.79
18.45
ROC (Joel Greenblatt) (%) 29.56
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 908 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.66 vs. MRK: 29.56 )
MRK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.91   Max: 130.04
Current: 29.56

10.91
130.04
Revenue Growth (3Y)(%) -0.10
MRK's Revenue Growth (3Y)(%) is ranked higher than
63% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. MRK: -0.10 )
MRK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -16.5   Max: 21.4
Current: -0.1

-16.5
21.4
EBITDA Growth (3Y)(%) 12.60
MRK's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. MRK: 12.60 )
MRK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.6   Max: 44.7
Current: 12.6

-17.6
44.7
EPS Growth (3Y)(%) 73.80
MRK's EPS Growth (3Y)(%) is ranked higher than
97% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. MRK: 73.80 )
MRK' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.7   Max: 73.8
Current: 73.8

-42.7
73.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MRK Guru Trades in Q4 2013

Ruane Cunniff 4,075 sh (New)
Louis Moore Bacon 10,000 sh (New)
George Soros 150,000 sh (New)
Jim Simons 2,018,534 sh (+700.05%)
Irving Kahn 2,525,376 sh (+105.56%)
Bill Frels 130,654 sh (+15.21%)
Ken Fisher 1,197,965 sh (+8.93%)
John Buckingham 34,302 sh (+3.42%)
RS Investment Management 1,633,719 sh (+1.99%)
Vanguard Health Care Fund 36,561,348 sh (+1.79%)
Richard Snow 5,410 sh (+0.46%)
John Hussman 2,625 sh (unchged)
Louis Moore Bacon 500,000 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Mark Hillman 17,807 sh (unchged)
Mario Gabelli 195,671 sh (unchged)
Bill Nygren 1,587,000 sh (unchged)
George Soros 129,300 sh (unchged)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Murray Stahl 48,071 sh (-0.1%)
Jeff Auxier 170,849 sh (-0.12%)
James Barrow 29,423,811 sh (-0.73%)
NWQ Managers 123,726 sh (-1.22%)
Dodge & Cox 48,798,496 sh (-2.67%)
Manning & Napier Advisors, Inc 409,182 sh (-3.05%)
HOTCHKIS & WILEY 1,018,710 sh (-3.81%)
Pioneer Investments 2,211,185 sh (-8.15%)
Charles Brandes 2,476,201 sh (-8.39%)
Tom Russo 4,536 sh (-20.92%)
Jeremy Grantham 9,665,336 sh (-27.28%)
Jean-Marie Eveillard 14,050 sh (-98.76%)
» More
Q1 2014

MRK Guru Trades in Q1 2014

Joel Greenblatt 3,567 sh (New)
David Dreman 4,431 sh (New)
Steven Cohen 705,823 sh (New)
Paul Tudor Jones 5,035 sh (New)
Jean-Marie Eveillard 2,236,839 sh (+15820.6%)
Ruane Cunniff 4,409 sh (+8.2%)
Pioneer Investments 2,345,288 sh (+6.06%)
Signature Select Canadian Fund 299,500 sh (+2.85%)
RS Investment Management 1,668,798 sh (+2.15%)
Robert Bruce 261,500 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Richard Snow 5,410 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Tom Russo 4,536 sh (unchged)
Louis Moore Bacon Sold Out
John Hussman Sold Out
John Buckingham Sold Out
HOTCHKIS & WILEY Sold Out
Bill Nygren Sold Out
George Soros Sold Out
Murray Stahl 48,051 sh (-0.04%)
Charles Brandes 2,451,125 sh (-1.01%)
Vanguard Health Care Fund 35,616,848 sh (-2.58%)
Jeff Auxier 164,199 sh (-3.89%)
Bill Frels 114,212 sh (-12.58%)
Manning & Napier Advisors, Inc 353,494 sh (-13.61%)
Mario Gabelli 160,316 sh (-18.07%)
Dodge & Cox 39,959,196 sh (-18.11%)
James Barrow 22,739,030 sh (-22.72%)
NWQ Managers 93,255 sh (-24.63%)
Ken Fisher 725,058 sh (-39.48%)
Irving Kahn 1,128,415 sh (-55.32%)
Jeremy Grantham 2,519,078 sh (-73.94%)
Jim Simons 196,200 sh (-90.28%)
» More
Q2 2014

MRK Guru Trades in Q2 2014

George Soros 86,800 sh (New)
Joel Greenblatt 126,844 sh (+3456.04%)
Ken Fisher 6,464,243 sh (+791.55%)
Jim Simons 795,534 sh (+305.47%)
Paul Tudor Jones 13,266 sh (+163.48%)
Pioneer Investments 4,256,501 sh (+81.49%)
Manning & Napier Advisors, Inc 380,192 sh (+7.55%)
Ruane Cunniff 4,609 sh (+4.54%)
Murray Stahl 48,271 sh (+0.46%)
James Barrow 22,793,207 sh (+0.24%)
Prem Watsa 12,000 sh (unchged)
Richard Snow 5,410 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Steven Cohen 17,200 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Mario Gabelli 160,316 sh (unchged)
David Dreman Sold Out
Charles Brandes 2,434,531 sh (-0.68%)
Irving Kahn 1,120,074 sh (-0.74%)
Tom Russo 4,386 sh (-3.31%)
Vanguard Health Care Fund 33,889,948 sh (-4.85%)
Bill Frels 107,546 sh (-5.84%)
Jeff Auxier 149,734 sh (-8.81%)
NWQ Managers 84,311 sh (-9.59%)
Dodge & Cox 35,960,137 sh (-10.01%)
Jean-Marie Eveillard 1,755,082 sh (-21.54%)
RS Investment Management 861,075 sh (-48.4%)
Jeremy Grantham 340,971 sh (-86.46%)
» More
Q3 2014

MRK Guru Trades in Q3 2014

Stanley Druckenmiller 329,600 sh (New)
Ray Dalio 14,141 sh (New)
Steven Cohen 321,100 sh (+1766.86%)
Joel Greenblatt 536,550 sh (+323%)
Paul Tudor Jones 31,725 sh (+139.15%)
Ruane Cunniff 4,784 sh (+3.8%)
Mario Gabelli 162,706 sh (+1.49%)
Robert Bruce 265,000 sh (+1.34%)
Ken Fisher 6,533,475 sh (+1.07%)
RS Investment Management 861,075 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Prem Watsa 12,000 sh (unchged)
George Soros Sold Out
James Barrow 22,769,088 sh (-0.11%)
NWQ Managers 83,811 sh (-0.59%)
Richard Snow 5,375 sh (-0.65%)
Manning & Napier Advisors, Inc 377,389 sh (-0.74%)
Bill Frels 106,735 sh (-0.75%)
Irving Kahn 1,109,189 sh (-0.97%)
Jim Simons 787,634 sh (-0.99%)
Tom Russo 4,336 sh (-1.14%)
Vanguard Health Care Fund 33,420,748 sh (-1.38%)
Jeff Auxier 147,484 sh (-1.5%)
Pioneer Investments 4,184,247 sh (-1.7%)
Dodge & Cox 35,057,668 sh (-2.51%)
Murray Stahl 46,821 sh (-3%)
Charles Brandes 2,320,288 sh (-4.69%)
Jean-Marie Eveillard 1,083,826 sh (-38.25%)
Signature Select Canadian Fund 163,400 sh (-45.44%)
Jeremy Grantham 118,890 sh (-65.13%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 323%0.24%$55.64 - $61.18 $ 59.581%536550
Jean-Marie Eveillard 2014-09-30 Reduce -38.25%0.1%$55.64 - $61.18 $ 59.581%1083826
George Soros 2014-09-30 Sold Out 0.04%$55.64 - $61.18 $ 59.581%0
Ray Dalio 2014-09-30 New Buy0.01%$55.64 - $61.18 $ 59.581%14141
Ken Fisher 2014-06-30 Add 791.55%0.7%$54.83 - $59.62 $ 59.584%6464243
Vanguard Health Care Fund 2014-06-30 Reduce -4.85%0.28%$54.83 - $59.62 $ 59.584%33889948
Dodge & Cox 2014-06-30 Reduce -10.01%0.23%$54.83 - $59.62 $ 59.584%35960137
Joel Greenblatt 2014-06-30 Add 3456.04%0.09%$54.83 - $59.62 $ 59.584%126844
Jean-Marie Eveillard 2014-06-30 Reduce -21.54%0.07%$54.83 - $59.62 $ 59.584%1755082
George Soros 2014-06-30 New Buy0.04%$54.83 - $59.62 $ 59.584%86800
David Dreman 2014-06-30 Sold Out 0.02%$54.83 - $59.62 $ 59.584%0
Irving Kahn 2014-03-31 Reduce -55.32%2.88%$49.49 - $57.47 $ 59.5810%1128415
Bill Nygren 2014-03-31 Sold Out 0.69%$49.49 - $57.47 $ 59.5810%0
James Barrow 2014-03-31 Reduce -22.72%0.48%$49.49 - $57.47 $ 59.5810%22739030
Dodge & Cox 2014-03-31 Reduce -18.11%0.45%$49.49 - $57.47 $ 59.5810%39959196
Jean-Marie Eveillard 2014-03-31 Add 15820.6%0.34%$49.49 - $57.47 $ 59.5810%2236839
HOTCHKIS & WILEY 2014-03-31 Sold Out 0.22%$49.49 - $57.47 $ 59.5810%0
Vanguard Health Care Fund 2014-03-31 Reduce -2.58%0.15%$49.49 - $57.47 $ 59.5810%35616848
Ken Fisher 2014-03-31 Reduce -39.48%0.06%$49.49 - $57.47 $ 59.5810%725058
George Soros 2014-03-31 Sold Out 0.06%$49.49 - $57.47 $ 59.5810%0
David Dreman 2014-03-31 New Buy0.02%$49.49 - $57.47 $ 59.5810%4431
John Hussman 2014-03-31 Sold Out 0.01%$49.49 - $57.47 $ 59.5810%0
NWQ Managers 2014-03-31 Reduce -24.63%0.01%$49.49 - $57.47 $ 59.5810%93255
Joel Greenblatt 2014-03-31 New Buy$49.49 - $57.47 $ 59.5810%3567
Irving Kahn 2013-12-31 Add 105.56%2.67%$45.09 - $50.18 $ 59.5824%2525376
Jean-Marie Eveillard 2013-12-31 Reduce -98.76%0.16%$45.09 - $50.18 $ 59.5824%14050
Leon Cooperman 2013-12-31 Sold Out 0.15%$45.09 - $50.18 $ 59.5824%0
Charles Brandes 2013-12-31 Reduce -8.39%0.14%$45.09 - $50.18 $ 59.5824%2476201
George Soros 2013-12-31 New Buy0.06%$45.09 - $50.18 $ 59.5824%150000
Ruane Cunniff 2013-12-31 New Buy$45.09 - $50.18 $ 59.5824%4075
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Merck & Co Inc

Bill Nygren Comments on Merck - Apr 10, 2014

We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Merck & Co Inc

A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio
Over the duration of the third quarter the Vanguard Health Care Fund added two new stocks to its holdings. The fund now holds on to 89 stocks valued at $39.18 billion. The following companies are Vanguard's top portfolio holdings. Read more...
Vanguard Health Care Fund's Top Quarterly Holdings
Over the duration of the first quarter the Vanguard Health Care Fund purchased added three new stocks to its holdings. The fund now holds on to 86 stocks valued at $35.6 billion. The following companies are Vanguard's top portfolio holdings. Read more...
Bill Nygren Comments on Merck
We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value. Read more...
Vanguard Health Care Fund’s Top Five
Over the duration of the fourth quarter the Vanguard Health Care Fund purchased added four new stocks to its holdings. The fund now holds on to 93 stocks valued at $32.35 billion. The following companies are Vanguard's top five portfolio holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 32.70
MRK's P/E(ttm) is ranked higher than
80% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.00 vs. MRK: 32.70 )
MRK' s 10-Year P/E(ttm) Range
Min: 6.67   Max: 139.89
Current: 32.7

6.67
139.89
P/B 3.80
MRK's P/B is ranked higher than
68% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. MRK: 3.80 )
MRK' s 10-Year P/B Range
Min: 1.72   Max: 7.27
Current: 3.8

1.72
7.27
P/S 4.08
MRK's P/S is ranked higher than
71% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.89 vs. MRK: 4.08 )
MRK' s 10-Year P/S Range
Min: 2.01   Max: 5.48
Current: 4.08

2.01
5.48
PFCF 16.23
MRK's PFCF is ranked higher than
95% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. MRK: 16.23 )
MRK' s 10-Year PFCF Range
Min: 7.8   Max: 86.81
Current: 16.23

7.8
86.81
EV-to-EBIT 31.22
MRK's EV-to-EBIT is ranked higher than
77% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.22 vs. MRK: 31.22 )
MRK' s 10-Year EV-to-EBIT Range
Min: 8.5   Max: 104
Current: 31.22

8.5
104
Shiller P/E 25.16
MRK's Shiller P/E is ranked higher than
88% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 165.76 vs. MRK: 25.16 )
MRK' s 10-Year Shiller P/E Range
Min: 8.23   Max: 25.95
Current: 25.16

8.23
25.95
Current Ratio 1.34
MRK's Current Ratio is ranked higher than
55% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. MRK: 1.34 )
MRK' s 10-Year Current Ratio Range
Min: 1.07   Max: 3.7
Current: 1.34

1.07
3.7
Quick Ratio 1.11
MRK's Quick Ratio is ranked higher than
58% of the 892 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. MRK: 1.11 )
MRK' s 10-Year Quick Ratio Range
Min: 0.8   Max: 3.44
Current: 1.11

0.8
3.44

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.97
MRK's Dividend Yield is ranked higher than
86% of the 519 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. MRK: 2.97 )
MRK' s 10-Year Dividend Yield Range
Min: 2.51   Max: 6.68
Current: 2.97

2.51
6.68
Dividend Payout 0.96
MRK's Dividend Payout is ranked higher than
100% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.30 vs. MRK: 0.96 )
MRK' s 10-Year Dividend Payout Range
Min: 0.16   Max: 4.22
Current: 0.96

0.16
4.22
Dividend growth (3y) 4.40
MRK's Dividend growth (3y) is ranked higher than
81% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. MRK: 4.40 )
MRK' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 14.8
Current: 4.4

0
14.8
Yield on cost (5-Year) 3.60
MRK's Yield on cost (5-Year) is ranked higher than
83% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. MRK: 3.60 )
MRK' s 10-Year Yield on cost (5-Year) Range
Min: 3.01   Max: 8.01
Current: 3.6

3.01
8.01
Share Buyback Rate 1.30
MRK's Share Buyback Rate is ranked higher than
89% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. MRK: 1.30 )
MRK' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -13
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.75
MRK's Price/Tangible Book is ranked higher than
58% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.24 vs. MRK: 14.75 )
MRK' s 10-Year Price/Tangible Book Range
Min: 3.19   Max: 3735
Current: 14.75

3.19
3735
Price/DCF (Projected) 1.52
MRK's Price/DCF (Projected) is ranked higher than
90% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.02 vs. MRK: 1.52 )
MRK' s 10-Year Price/DCF (Projected) Range
Min: 0.75   Max: 3.04
Current: 1.52

0.75
3.04
Price/Median PS Value 1.30
MRK's Price/Median PS Value is ranked higher than
69% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. MRK: 1.30 )
MRK' s 10-Year Price/Median PS Value Range
Min: 0.68   Max: 2.07
Current: 1.3

0.68
2.07
Price/Graham Number 4.56
MRK's Price/Graham Number is ranked higher than
73% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.05 vs. MRK: 4.56 )
MRK' s 10-Year Price/Graham Number Range
Min: 1.08   Max: 36.98
Current: 4.56

1.08
36.98
Earnings Yield (Greenblatt) 3.20
MRK's Earnings Yield (Greenblatt) is ranked higher than
77% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. MRK: 3.20 )
MRK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 11.8
Current: 3.2

1
11.8
Forward Rate of Return (Yacktman) 0.50
MRK's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 497 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.05 vs. MRK: 0.50 )
MRK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.2   Max: 22.1
Current: 0.5

-6.2
22.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0QAH.UK, MRK.France, 6MK.Germany, MRCK34.Brazil, MRK.Mexico, MRK.Argentina, MRK.Chile,
Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
T Rowe Price's Top Stakes for the Third Quarter Dec 09 2014 
You Should Hold Merck According to Dividends Generation Nov 21 2014 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
Kahn Brothers' Third Quarter Numbers Nov 07 2014 
Dividend Aristocrats In Focus Parts 30: Sigma-Aldrich Oct 28 2014 
What is Abner Herrman Investing In? Oct 16 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Reasons Why I Will Bet on Sigma Sep 26 2014 


More From Other Websites
FDA OKs Cubist antibiotic for serious infections Dec 19 2014
[$$] FDA Approves Cubist's Experimental Antibiotic Zerbaxa Dec 19 2014
FDA Approves Second Cubist Antibiotic Of 2014 Dec 19 2014
Merck Begins Tender Offer to Acquire Cubist Dec 19 2014
Merck buys Swiss biotech with promising cancer drug Dec 18 2014
Merck buys Swiss biotech with promising cancer drug Dec 18 2014
BUZZ-U.S. STOCKS ON THE MOVE-Bellicum Pharma, OvaScience, Comstock Dec 18 2014
New GSK shingles vaccine may challenge Merck after strong test data Dec 18 2014
[$$] Merck Acquires OncoEthix for Up to $375 Million Dec 18 2014
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for... Dec 18 2014
Call buyers take a dose of Merck Dec 18 2014
Options Traders Buy the Pullback in Pharmaceuticals Giant Merck Dec 18 2014
Business events scheduled for Tuesday Dec 15 2014
Business events scheduled for Tuesday Dec 15 2014
The Zacks Analyst Blog Highlights: Chevron, Statoil, Merck, Boeing and General Electric Dec 15 2014
MERCK & CO., INC. Financials Dec 13 2014
Merck KGaA -- Moody's downgrades Merck KGaA's ratings to Baa1; negative outlook Dec 12 2014
India caps prices of 52 more "essential" drugs - NPPA Dec 12 2014
India caps prices of 52 more "essential" drugs - pricing authority Dec 12 2014
Merck Reveals Data from Breast Cancer Study on Keytruda Dec 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK